

OPEN

Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxane) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial: Erratum

In the article “Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxane) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer Stage 1 of a Simon 2 Stage Clinical Trial”,¹ which appeared in Volume 94, Issue 52 of *Medicine*, the word tyxan was spelled incorrectly as tyxane. The article has since been corrected online.

REFERENCE

1. Tai C-J, Wang C-K, Tai C-J, et al. Evaluation of safety and efficacy of salvage therapy with sunitinib, docetaxel (tyxane) and cisplatinum followed by maintenance vinorelbine for unresectable/metastatic nonsmall cell lung cancer stage 1 of a Simon 2 stage clinical trial. *Medicine*. 94;52:e2303.